Log in Register
Menu

Anti-CD49b [31H4]

Info

Catalogue Number 152485
Applications ELISA FACS IP
Antigen/Gene or Protein Targets Integrin alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)
Synonyms Integrin Subunit Alpha 2; Alpha 2 Subunit Of VLA-2 Receptor; Platelet Membrane Glycoprotein Ia; CD49 Antigen-Like Family Member B; Collagen Receptor; CD49B; GPIa; Very Late Activation Protein 2 Receptor; Alpha-2 Subunit; Human Platelet Alloantigen System; Platelet Glycoprotein GPIa; VLA-2 Subunit Alpha; CD49b Antigen; HPA-5; VLA-2; VLAA2; BR
Reactivity Human
Relevance CD49b also known as integrin alpha-2, VLA-2 subunit alpha or collogen receptor. CD49b is a 1181 amino acid ¦130 kDa single pass type-1 transmembrane glycoprotein which forms a heterodimer with integrin beta-1 and mediates the adhesion of platelets and other cell types to the extracellular matrix. Loss of the encoded protein is associated with bleeding disorder platelet-type 9. Antibodies against this protein are found in several immune disorders, including neonatal alloimmune thrombocytopenia.
Host Mouse
Immunogen Purified human b1 integrin preparation from HT1080 fibrosarcoma cell extract.
Subclass IgG1
Myeloma Used P3X63Ag8.653
Notes Does not cross-react with Rat.
Mouse anti Human CD49b antibody, clone 31H4 has been identified as being capable of immunoprecipitating the integrin a2 subunit from human cell-lines surface labelled with 125I. It has been confirmed specific to a2 by relative expression of antigen on various cell lines by flow cytometry, and recognition of affinity purified a2b1 in dot blots.
Research Area Adhesion, Cell Signaling & Signal Transduction, Immunology

References: 8 entries

Tanaka et al. 2012. Int J Oncol. 41(5):1837-44. PMID: 22923148.

Tanaka et al. 2012. Oncol Rep. 28(1):330-6. PMID: 22552543.

Tanaka et al. 2010. Int J Oncol. 37(1):125-31. PMID: 20514404.

Tanaka et al. 2009. Int J Mol Med. 23(2):173-80. PMID: 19148540.

Tanaka et al. 2008. Int J Mol Med. 22(5):581-7. PMID: 18949377.

Tanaka et al. 2008. Oncol Rep. 20(1):13-23. PMID: 18575713.

Tanaka et al. 2006. Oncol Rep. 15(4):939-47. PMID: 16525683.

Tanaka et al. 2005. Oncol Rep. 14(4):941-8. PMID: 16142355.


Add a reference

References: 8 entries

Tanaka et al. 2012. Int J Oncol. 41(5):1837-44. PMID: 22923148.

Tanaka et al. 2012. Oncol Rep. 28(1):330-6. PMID: 22552543.

Tanaka et al. 2010. Int J Oncol. 37(1):125-31. PMID: 20514404.

Tanaka et al. 2009. Int J Mol Med. 23(2):173-80. PMID: 19148540.

Tanaka et al. 2008. Int J Mol Med. 22(5):581-7. PMID: 18949377.

Tanaka et al. 2008. Oncol Rep. 20(1):13-23. PMID: 18575713.

Tanaka et al. 2006. Oncol Rep. 15(4):939-47. PMID: 16525683.

Tanaka et al. 2005. Oncol Rep. 14(4):941-8. PMID: 16142355.


Add a reference

References: 8 entries

Tanaka et al. 2012. Int J Oncol. 41(5):1837-44. PMID: 22923148.

Tanaka et al. 2012. Oncol Rep. 28(1):330-6. PMID: 22552543.

Tanaka et al. 2010. Int J Oncol. 37(1):125-31. PMID: 20514404.

Tanaka et al. 2009. Int J Mol Med. 23(2):173-80. PMID: 19148540.

Tanaka et al. 2008. Int J Mol Med. 22(5):581-7. PMID: 18949377.

Tanaka et al. 2008. Oncol Rep. 20(1):13-23. PMID: 18575713.

Tanaka et al. 2006. Oncol Rep. 15(4):939-47. PMID: 16525683.

Tanaka et al. 2005. Oncol Rep. 14(4):941-8. PMID: 16142355.


Add a reference


This reagent does not have any reviews at the moment.